ClinicalTrials.gg
RecruitingNCT06632262Updated Nov 19, 2024

A Phase 2 Clinical Study of ABSK061 and ABSK043

A Phase 2 interventional study of ABSK061 + ABSK043 and ABSK061+ABSK043 in combination with CAPOX in HER2-Gastric/Gastroesophageal Junction Cancer, Urothelial Carcinoma and Non-Small Cell Lung Cancer, sponsored by Abbisko Therapeutics Co, Ltd. Recruiting at 21 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-11-19.

Sponsored by Abbisko Therapeutics Co, Ltd (part of Abbisko Cayman Limited) · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Nov 2024; still recruiting 2 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
202
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 88 studies in Carcinoma, Transitional Cell with a site in China — 51 open to participants now, 56 under way, 9 of them phase 3. Carcinoma, Transitional Cell · China.

Planned enrollment
18th of 69
202 · median 60
Started
2024
with 9 others
Phase 2
30 of 88
18 open now
Primary completion
2029-11
later than 53 of 55 live
Registered
53rd of 88
by date
Lead sponsor
3 of 88
Abbisko Therapeutics Co, Ltd

Among the 88 studies in Carcinoma, Transitional Cell with a site in China, this one is the 18th largest by planned enrollment of the 69 interventional ones that give a count, is one of 10 that started in 2024, is one of 30 in phase 2, reaches primary completion later than 53 of the 55 other live ones, and was the 53rd registered.

Carcinoma, Transitional Cell

632 studies on the registry are indexed under Carcinoma, Transitional Cell; 180 are open to participants now.

Browse Carcinoma, Transitional Cell studies →

Open to participants now

51 of the 88 studies in Carcinoma, Transitional Cell with a site in China are open now. Recruiting first, the newest first:

46 more — sign in →

All 51 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 147 Carcinoma, Transitional Cell studies recruiting now, 121 (82%) set no upper age limit and 11 (7%) stop at 75 or younger; 4 take children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 88 studies in Carcinoma, Transitional Cell with a site in China, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the anti-tumor activity of ABSK061 + ABSK043 in terms of overall response rate (ORR) in in Patients with Metastatic/Unresectable Solid Tumors with FGFR2/3 Alterations

Read the detailed description

ABSK061 is a selective and potent pan FGFR 2/3 inhibitor with demonstrated clinical activity in participants with a variety of FGFR inhibitors in a variety of solid tumors.

ABSK043 is a small molecule PD-L1 inhibitor with good oral bioavailability, high selectivity and high activity, and is currently being developed for the treatment of multiple cancers and potential non-oncology indications.

This study targets the underlying altered biology of FGFR-driven tumors irrespective of solid tumor histology subtype. The study consists of screening phase, treatment phase and the post treatment follow-up phase (from the end of treatment visit until the participant has died, withdraws consent, is lost to follow-up, or the end of study, whichever comes first). End of study is considered of the last visit of the last patient in this trial or the procedures shown in the schedule, or 12 months after the first dose of the last enrolled patient, whichever occurs first.

03

Conditions studied

  • HER2-Gastric/Gastroesophageal Junction Cancer
  • Urothelial Carcinoma
  • Non-Small Cell Lung Cancer
  • Solid Tumors
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients must have a measurable target lesion (per v1.1) (not applicable to expansion cohort 1) where:
  • Dose Escalation: patients with confirmed solid tumors who have progressed after standard of care, are unable to tolerate standard therapy, or have no standard of care currently available:
  • Patients must have the a central laboratory or previous test report confirming FGFR2/3 gene activatingon alterations (including FGFR2/3 activating mutations, fusions/rearrangements, or FGFR2 amplifications) or overexpression in tumor tissue or blood based on central laboratory test or previous test reports.
  • Expansion Phase:
  • Cohort 1 (-gastric/gastroesophageal junction cancer)
  • Histologically or cytologically confirmed /unresectable gastric/gastroesophageal junction cancer, HER2 test negative
  • The patient had FGFR2 amplification or overexpression in tumor tissue confirmed by a central laboratory test or a previous test report (previous test report only applied to FGFR2 amplification)
  • Patients need to provide prior tumor tissue or willingness to undergo if no prior tumor tissue or insufficient quantity is required
  • No prior (or up to one course of chemotherapy) systemic therapy for advanced gastric/gastroesophageal junction cancer, or disease progression more than 6 months after the end of the last prior therapy
  • Patients must have a measurable target lesion or evaluable non-target lesion (per RECIST v1.1)
  • Cohort 2 (urothelial carcinoma)
  • Histologically or cytologically confirmed metastatic/unresectable urothelial carcinoma with other histologic differentiation (including adenoid, squamous, or other types)
  • Patients must have the prespecified a central laboratory or previous test report confirming the presence of a specific FGFR3 mutation or overexpression, FGFR2/3 fusion in tumor tissue or blood based on central laboratory test or previous test reports.
  • No prior (or up to one course of chemotherapy) systemic therapy for advanced urothelial carcinoma, or disease progression more than 12 months after the end of the last prior adjuvant therapy, or disease progression or intolerable toxicity after at least one line of standard of care (per local standard of care or guidelines)
  • Cohort 3 (non-small cell lung cancer)
  • Histologically or cytologically confirmed metastatic/unresectable non-small cell lung cancer (NSCLC)
  • Patients must have the prespecified a central laboratory or previous test report confirming the presence of a specific FGFR2/3 mutation, fusion, or overexpression in tumor tissue or blood based on central laboratory test or previous test reports.
  • Disease progression or intolerable toxicity after at least one prior line of standard of care or targeted therapy for driver mutations (according to local standards of care or guidelines)
  • Cohort 4 (Other Solid Tumors)
  • Histologically or cytologically confirmed metastatic/unresectable other solid tumors
  • Patients must have a central laboratory or previous test report confirmingthe FGFR2/3 gene activationng alterations (including FGFR2/3 activating mutations, fusions/rearrangements, or FGFR2 amplifications) or overexpression in tumor tissue or blood based on central laboratory test or previous test reports.
  • Disease progression or intolerable toxicity after at least one prior line of standard therapy.

Exclusion criteria

Exclusion Criteria:

  • Previous treatment with an FGFR pathway inhibitor or a multi-kinase inhibitor designed to inhibit FGFR (consultation with the sponsor is recommended)
  • Active or medical history of diseases, including but not limited to myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegener's granulomatosis, Sjögren's syndrome, Guillain-Barré syndrome, multiple sclerosis, vasculitis, or glomerulonephritis. (Patients with type 1 diabetes mellitus, hypothyroidism requiring hormone replacement therapy only, skin diseases that do not require systemic treatment (e.g., vitiligo, psoriasis, or alopecia) are allowed.Uncertain autoimmune-related status should be discussed with the sponsor).
  • The patient had clinically symptomatic lung disease (e.g. interstitial pneumonia, pulmonary fibrosis, severe radiation pneumonitis, etc.) requiring systemic therapy within 6 months prior to enrollment.
  • Known other that are in progression or require active treatment (except cured skin cancer, carcinoma in situ of the cervix, basal cell carcinoma, focal prostate cancer with a Gleason score of 6, focal prostate cancer with a Gleason score of 3 + 4 and treated for more than 6 months at screening).
  • Time from the end of other prior anti-tumor therapy to the first dose of study drug: major surgery (palliative treatment for local lesions is allowed), in vitro and in vivo radiotherapy (> 30% bone marrow exposure) is less than 4 weeks; received immunotherapy or other antibody study drugs within 4 weeks prior to the start of study treatment; received chemotherapy (within 6 weeks of the start of study treatment with nitrosourea or mitomycin chemotherapy), endocrine therapy, and small molecule targeted therapy within 2 weeks or 5 half-lives, whichever is shorter.
  • Patients who have not recovered to ≤ Grade 1 ( v5.0) from toxicities caused by prior chemotherapy, radiotherapy, and other anti-tumor therapies, including immunotherapy (except for alopecia as permitted by eligibility criteria or alopecia, vitiligo, stable hypothyroidism controlled by hormone replacement therapy, ≤ Grade 2 hearing loss, or ≤ Grade 2 peripheral neurotoxicity).
  • History of ≥ Grade 3 immune-related adverse events with prior therapy.
  • (Expansion Cohort 3 (non-small cell lung cancer)) Patients were previously identified with driver mutations (according to local diagnostic and therapeutic criteria or guidelines such as EGFR mutation, ALK rearrangement positive, KRAS G12C mutation positive, NTRK1/2/3 gene fusion positive, RET fusion positive, MET exon 14 skipping mutation, BRAF V600E mutation positive, ROS1 rearrangement positive) and did not receive targeted therapy.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
202 participants (estimated)

Study arms

  • Experimental
    Cohort 1

    HER2-Gastric/Gastroesophageal Junction Cancer

    Drug: ABSK061+ABSK043 in combination with CAPOX

  • Experimental
    Cohort 2

    Urothelial carcinoma

    Drug: ABSK061 + ABSK043

  • Experimental
    Cohort 3

    Non-small cell lung cancer

    Drug: ABSK061 + ABSK043

  • Experimental
    Cohort 4

    Other solid tumors

    Drug: ABSK061 + ABSK043

Interventions

  • DrugABSK061 + ABSK043

    Drug pages: ABSK061 · PD-L1 Inhibitor ABSK043

    Participants with fibroblast growth factor receptor (FGFR) mutations and FGFR gene fusions will receive a dose of ABSK061 + ABSK043 oral capsule until disease progression, intolerable toxicity, withdrawal of consent, decision by the investigator to discontinue treatment, or end of data collection timepoint if there is clinical benefit in the opinion of the investigator, has been achieved.

  • DrugABSK061+ABSK043 in combination with CAPOX

    Drug pages: ABSK061 · PD-L1 Inhibitor ABSK043

    Participants with HER2-Gastric/Gastroesophageal Junction Cancer and fibroblast growth factor receptor 2( FGFR2 ) amplification and overexpression will receive a dose of ABSK061 + ABSK043 oral capsule in combination with CAPOX until disease progression, intolerable toxicity, withdrawal of consent, decision by the investigator to discontinue treatment, or end of data collection timepoint if there is clinical benefit in the opinion of the investigator, has been achieved.

06

What researchers measure

Primary outcomes

  1. Incidence of Dose limited toxicity (DLT)

    Number of Participants With Adverse Event (AE), Serious Adverse Event, (SAE) and Laboratory Abnormalities Defined as Dose Limiting Toxicities (DLT)

    Time frame: At the end of Cycle 1 (each cycle is 28 days)

  2. To assess the tolerability of ABSK061 + ABSK043 in combination with CAPOX in patients with first-line gastric/gastroesophageal junction cancer

    Number of Participants With Adverse Event (AE), Serious Adverse Event, (SAE) and Laboratory Abnormalities Defined as Dose Limiting Toxicities (DLT)

    Time frame: At the end of Cycle 1 (each cycle is 21 days)

  3. To assess the anti-tumor activity of ABSK061 + ABSK043 in combination with CAPOX as the primary endpoint of Progression-free survival (PFS) in first-line treatment of patients with metastatic/unresectable HER2-gastric/gastroesophageal junction cancer

    PFS, as assessed by the investigator per RECIST v1.1

    Time frame: up to 5 years

  4. To assess the anti-tumor activity of ABSK061 + ABSK043 in patients with metastatic/unresectable urothelial cancer with FGFR2/3 activating alteration or FGFR3 overexpression, with Objective response rate (ORR) as the primary endpoint

    Objective response rate (ORR): complete response and partial response determined by the investigator according to RECIST v1.1 and to be confirmed

    Time frame: up to 5 years

  5. To assess the anti-tumor activity of ABSK061 + ABSK043 in patients with non-small cell lung cancer withFGFR2/3 activating alteration or overexpression as the primary endpoint

    PFS, as assessed by the investigator per RECIST v1.1

    Time frame: up to 5 years

  6. To assess the anti-tumor activity of ABSK061 + ABSK043 in patients with metastatic/unresectable other advanced solid tumors with FGFR2/3 activatingon alteration or overexpression as the primary endpoint

    Objective response rate (ORR): complete response and partial response determined by the investigator according to RECIST v1.1 and to be confirmed

    Time frame: up to 5 years

Secondary outcomes

  1. Overall Response Rate as Assessed by Investigator

    Objective response rate (ORR): complete response and partial response determined by the investigator according to RECIST v1.1 and to be confirmed

    Time frame: Up to 5 years

  2. Duration of Response (DOR)

    DOR is the duration from the date of initial documentation of a response to the date of first documented evidence of progressive disease (or relapse for participants who experience CR during the study), or death, whichever comes first.

    Time frame: Up to 5 years

  3. Disease Control Rate (DCR)

    DCR is defined as the percentage of participants with CR, PR or stable disease (SD).DCR is defined as the percentage of participants with CR, PR or stable disease (SD).

    Time frame: up to 5 years

  4. Progression Free Survival (PFS)

    PFS is the duration from the date of the first dose of study drug until the date of first documented evidence of progressive disease (or relapse for participants who experience CR during the study) or death, whichever comes first.

    Time frame: up to 5 years

  5. Overall Survival (OS)

    OS will be measured from the date of first dose of study drug to the date of the participant\'s death.

    Time frame: up to 5 years

  6. Maximum observed concentration(Cmax)

    To assess the PK profile of ABSK061 and ABSK043 after dosing of ABSK061 + ABSK043

    Time frame: From date of enrollment #Day1# until the date of end of treatment visit, assessed up to 12 months

  7. Area under the concentration-time curve(AUC)

    To assess the PK profile of ABSK061 and ABSK043 after dosing of ABSK061 + ABSK043

    Time frame: From date of enrollment #Day1# until the date of end of treatment visit, assessed up to 12 months

  8. Time to maximum observed concentration(Tmax)

    To assess the PK profile of ABSK061 and ABSK043 after dosing of ABSK061 + ABSK043

    Time frame: From date of enrollment #Day1# until the date of end of treatment visit, assessed up to 12 months

07

Study locations

1 of 21 sites recruiting
  • Guizhou Provincial People'S Hospital
    Guiyang, Guizhou 550000, China
    Not yet recruiting
    • Jie Luo · Contact1654377211@qq.com · 86851-85607982
    • Shisheng Tan, Doctor · Contact
  • The Affiliated Hospital of Guizhou Medical University
    GuiYang, Guizhou 550000, China
    Not yet recruiting
    • Peng Du · Contact19044055@qq.com · +86(851)86752817
    • Jing Wang, Doctor · Contact
  • The Fourth Hospital of Hebei Medical University
    Shijiazhuang, Heibei 050000, China
    Not yet recruiting
  • Harbin Medical University Cancer Hospital
    Harbin, Heilongjiang 150000, China
    Not yet recruiting
    • Jinlu Wang · Contactsylcyj609@163.com · 0451-86298192
    • Yanqiao Zhang, Doctor · Contact
  • Henan Cancer Hospital
    Zhengzhou, Henan 450000, China
    Not yet recruiting
  • Hunan Central Hospital
    Changsha, Hunan 410000, China
    Not yet recruiting
  • Jiangxi Cance Hospital
    Nanchang, Jiangxi 330000, China
    Not yet recruiting
    • Yuan Gao · Contactjxzljgb@126.com · 0791-88331395
    • Bo Yi, Doctor · Contact
  • Liaoning Cancer Hospital and Institute
    Shenyang, Liaoning 110000, China
    Not yet recruiting
    • Yi Wang · Contact564066425@qq.com · 024-81916651
    • Yan Zhao, Doctor · Contact
  • Cancer Hospital of Shandong First Medical University
    Jinan, Shandong 250000, China
    Not yet recruiting
    • Yuanyuan Lv · Contactywb234@126.com · 0531-67626063
    • Yan Zhang, Doctor · Contact
    • Zuoxing Niu, Doctor · Contact
  • ZhongShan Hospital Fudan University
    Shanghai, Shanghai 200000, China
    Recruiting
  • Xiangyang Central Hospital
    Xiangyang, Sichuang 610000, China
    Not yet recruiting
  • Changzhi People's Hospital
    Changzhi, China
    Not yet recruiting
  • West China Hospital, Sichuan University
    Chengdu, China
    Not yet recruiting
    • Ying Qian · Contacthuaxigcp@163.com · 028-85422707
    • Guowei Che, Doctor · Contact
  • The First Hospital of China Medical University
    Hangzhou, China
    Not yet recruiting
    • Yuqing Zhang · Contactcmu_lawyer@163.com · +8615140139773
    • Funan Liu, Doctor · Contact
  • Zhejiang Provincial People'S Hospital
    Hangzhou, China
    Not yet recruiting
  • Tianjin Medical University Cancer Institute and Hospital
    Tianjin, China
    Not yet recruiting
  • Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science & Technology
    Wuhan, China
    Not yet recruiting
    • Chang Shu · Contacttongjigcp@163.com · 027-83663940
    • Xianglin Yuan, Doctor · Contact
  • First Hospital of Shanxi Medical University
    Xi'an, China
    Not yet recruiting
    • Yilai Song · Contactlzgwyy@sina.com · 0351-4639072
    • Yusheng Wang, Doctor · Contact
  • Shanxi Cancer hospital (Shanxi Cancer institute)
    Xi'an, China
    Not yet recruiting
  • First Affiliated Hospital of Xiamen University
    Xiamen, China
    Not yet recruiting
    • Mingxia Fan · Contactxdfygcp@sina.com · 0592-2137232
    • Feng Ye, Doctor · Contact
  • The Affiliated Hospital of Xuzhou Medical University
    Xuzhou, China
    Not yet recruiting
    • Haijing Jiang · Contactxyfy2369@163.com · 0516-85802369
    • Jun Song, Doctor · Contact
08

References and documents

Individual participant data

Plan to share: Yes

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2024 (actual). Primary completion is estimated for Nov 2029, 60 months after the start.

Of 119 phase 2 interventional studies under Carcinoma, Transitional Cell, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 102. This study's planned 60 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 1, 2024
First posted
Oct 9, 2024
StartActual
Nov 13, 2024
Primary completionEst.
Nov 30, 2029
CompletionEst.
Jun 30, 2030
Last update
Nov 19, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 19, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06632262
Responsible party
Sponsor
First posted
Oct 9, 2024
Start date
Nov 13, 2024
Primary completion
Nov 30, 2029 (estimated)
Completion
Jun 30, 2030 (estimated)
Last update
Nov 19, 2024

Study contacts

Yuan Lu, Doctor
Contact
clinical@abbisko.cn
+86(21)68910052
Tianshu Liu, Doctor
principal investigator · Fudan University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: ABSK061 · PD-L1 Inhibitor ABSK043

Start the discussion